Genitourinary Cancers

In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance.

Intravesical rAd-IFNα/Syn3 showed promising response rates, a tolerable treatment schedule, and acceptable toxicity among patients with high-grade, nonmuscle-invasive bladder cancer, refractory or relapsed after bacillus Calmette-Guérin therapy.

Suspicious pathology from kidney tumors was significantly associated with testing positive for fumarate hydratase mutations, which may aid in the early diagnosis of hereditary leiomyomatosis and renal cell carcinoma.

Pembrolizumab is associated with longer overall survival and fewer treatment-related toxicities vs chemotherapy for patients with advanced urothelial carcinoma.

The Decipher prostate cancer gene-expression classifier can predict patients’ risk of metastasis and prostate cancer-specific mortality using biopsy specimens prior to radical prostatectomy or radiotherapy plus androgen deprivation.

Ahead of the ASCO-sponsored 2017 Genitourinary Cancers Symposium being held February 16th to February 18th in Orlando, Florida, we spoke with Dr. Ana Aparicio about the role of androgen receptors in prostate cancer.

Antibiotics administered less than a month before initiation of immunotherapies for patients with advanced kidney cancer might impair tumor control, according to a retrospective analysis.

Though it is used infrequently, lymph node dissection with higher yield of lymph nodes is associated with lower all-cause mortality among patients with urothelial carcinoma of the upper urinary tract who undergo nephroureterectomy.

A long-term study found that adding 24 months of antiandrogen therapy with bicalutamide to salvage radiation therapy increased overall survival and prostate cancer–specific survival compared with placebo in men who underwent radical prostatectomy.

Breaks from active sunitinib treatment for patients with treatment-naive metastatic renal cell carcinoma may be possible without effecting clinical efficacy.

The use of multi-parametric magnetic resonance imaging could allow more than a quarter of men with high prostate-specific antigen levels to avoid undergoing transrectal ultrasound-guided prostate biopsy.

We spoke with Dr. Monika Joshi on the use of radiation therapy and durvalumab in patients with locally advanced bladder cancer.

A new study is suggesting that by targeting a specific microRNA molecule (miR-141) it may be possible to stop the cascade of events that lead to metastasis in men with prostate cancer.

A study has shown a link between metabolic toxicities and the efficacy of mTOR inhibitors for the treatment of metastatic renal cell carcinoma.

In prostate cancer patients, a PSA nadir value of > 0.5 ng/mL after radiation therapy and androgen deprivation therapy can identify patients at a high risk of death.

The PD-1 inhibitor pembrolizumab showed promising antitumor activity and acceptable safety in patients with advanced urothelial cancer, in a phase I trial.

A new German multicenter study is suggesting that lutetium-177 (Lu-177)-labeled PSMA-617 may be a promising new therapeutic agent for radioligand therapy in men with metastatic castration-resistant prostate cancer.

In patients with upper tract urothelial carcinoma, adjuvant chemotherapy following radical nephroureterectomy confers a survival advantage compared with observation following radical nephroureterectomy.

A new study is suggesting it may be possible to shut down the circuits that drive the high tumorigenicity of prostate cancer cells leading to castration-resistant prostate cancer.

An early study looking at the combination of the ALK1 inhibitor dalantercept plus axitinib showed clinical activity in patients with advanced renal cell carcinoma.

The FDA has concluded that pioglitazone, used to treat type 2 diabetes, may be linked to an increased risk of bladder cancer.

An increasing percentage of men over the age of 75 who are diagnosed with prostate cancer have distant metastases at the time of diagnosis, according to a new study.

Although the use of sorafenib in patients with treatment-naive metastatic renal cell carcinoma demonstrated clinical benefit, a phase IIb study did not support the use of dose escalation in these patients.

Vascular-targeted photodynamic therapy with padeliporfin was significantly better than active surveillance over a 2-year period in men with low-risk localized prostate cancer.

The US Food and Drug Administration has accepted the first Biologics License Application for durvalumab (MEDI4736) to treat patients with urothelial cancer (UC) for whom cisplatin failed to stop disease progression.